Cambridge Open Engage home
What is Cambridge Open Engage?
How to Submit
Browse
About
News [opens in a new tab]

A Pathogen Mimetic Molecule Induces Highly Amplified Synergistic Immune Activation to Vaccination via Activation of Multiple Signaling Pathways

19 October 2020, Version 1
Working Paper
This content is a preprint and has not undergone peer review at the time of posting.

Abstract

We developed a small-molecule trimeric PRR agonist-based adjuvant inspired by the stimulation pattern of a pathogen. This molecule generated by covalently linking TLR2/6 agonist, NOD2 agonist, and NLRP3 inflammasome activator, stimulates multiple subfamilies of PRRs in a spatially defined manner resulting in an amplified innate immune response in vitro. Moreover, it elicits both stronger humoral and cellular immune responses in vivo.

Keywords

adjuvant • vaccines• pathogens • immunostimulants • antigen • pathogen associated molecular patterns • pattern recognition receptors

Supplementary materials

Title
Description
Actions
Title
Materials and Methods
Description
Actions
Title
chemrxiv manuscript
Description
Actions
Title
Materials and Methods
Description
Actions

Comments

Comments are not moderated before they are posted, but they can be removed by the site moderators if they are found to be in contravention of our Commenting Policy [opens in a new tab] - please read this policy before you post. Comments should be used for scholarly discussion of the content in question. You can find more information about how to use the commenting feature here [opens in a new tab] .
This site is protected by reCAPTCHA and the Google Privacy Policy [opens in a new tab] and Terms of Service [opens in a new tab] apply.

Version History

Oct 19, 2020 Version 1

Metrics

1,291
288
0
Views
Downloads
Citations

License

CC logo
CC
BY logo
BY
NC logo
NC
ND logo
ND
The content is available under CC BY NC ND 4.0 [opens in a new tab]

DOI

10.26434/chemrxiv.13105316.v1
D O I: 10.26434/chemrxiv.13105316.v1 [opens in a new tab]

Funding

NIH (5U01AI124286-05)

Author’s competing interest statement

No conflict of interest

Share